Abstract
Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.
Keywords: Hematopoietic stem cells, gene therapy, central nervous system, lysosomal storage disorders, blood-brain-barrier, protein delivery, brain parenchyma, ventricular space
Current Gene Therapy
Title:Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders
Volume: 12 Issue: 5
Author(s): Alessandra Biffi
Affiliation:
Keywords: Hematopoietic stem cells, gene therapy, central nervous system, lysosomal storage disorders, blood-brain-barrier, protein delivery, brain parenchyma, ventricular space
Abstract: Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.
Export Options
About this article
Cite this article as:
Biffi Alessandra, Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders, Current Gene Therapy 2012; 12 (5) . https://dx.doi.org/10.2174/156652312802762572
DOI https://dx.doi.org/10.2174/156652312802762572 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Yin and Yang of Inflammation
Current Molecular Medicine Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of MCP -1 in Atherosclerosis
Current Pharmaceutical Design The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Current Drug Targets Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Therapeutic Indications and Action Mechanisms of Bilirubin: Suggestions from Natural Calculus Bovis
Current Signal Transduction Therapy Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Current Drug Targets A Review of Nanocarrier-Based CNS Delivery Systems
Current Drug Delivery Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Current Molecular Medicine Gene and Cancer Therapy - Pseudorabies Virus: A Novel Research and Therapeutic Tool?
Current Gene Therapy Aminooxy-Acetic Acid Inhibits Experimental Autoimmune Uveitis by Modulating the Balance between Effector and Regulatory Lymphocyte Subsets
Current Molecular Medicine Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis
Current Drug Targets - Inflammation & Allergy Bisphosphonates-Anti-Inflammatory Properties
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Epigenetics in Multiple Sclerosis: Molecular Mechanisms and Dietary Intervention
Central Nervous System Agents in Medicinal Chemistry